`
`ATDA/ONC/NS
`
`FTY720
`
`Sphingosine 1-phosophate receptor agonists
`
`Effects of FTY720 on experimental autoimmune
`encephalomyelitis-induced angiogenesis (acute and
`relapsing)
`
`Authorm):
`
`Hiestand P, Schnell C} Seabrook T, Littlewood-Evans A
`
`Responsible author Hiesiand P
`
`Document type:
`
`Release Ready Method/Study Report
`
`Document status:
`
`Approved
`
`Release date:
`
`12-May—2009
`
`Number of pages:
`
`26
`
`Document number:
`
`FED-200800078
`
`Property of Novartis
`Confidenfia
`Maynotbeused,mvumed,puN$hedoroWenMsed$cbsed
`without the consent of Novartis
`
`122800016.00001
`
`Apotex v. Novartis
`lPR2017-00854
`
`NOVARTIS 2070
`
`1
`
`Apotex v. Novartis
`IPR2017-00854
`NOVARTIS 2070
`
`1
`
`
`
`Novartis
`RD72008~00078
`
`Signatures
`
`Author
`
`Name
`
`Confidentia!
`
`Raw 2
`FTYTZO
`
`Signature
`J”
`
`,
`
`Date
`
`Hiestand P
`
`Head of Autoimmunity and Transplantation, Basel
`Name
`Signature
`'7 W
`// Jr/
`
`My”
`.
`
`fl
`,4“ 4‘
`
`Patei, D
`
`5
`
`A,
`
`Date
`
`TV“
`
`1/
`
`122800016.00002
`
`2
`
`